BioSpace News Archive

Business

Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights

Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, reported its unaudited financial results for the three and six months ended June 30, 2023.

August 15, 2023
·
15 min read
Biotech Beach

USPTO Rejects Patent Claims Asserted by Magnolia Medical, Inc. against Kurin, Inc.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that the US Patent and Trademark Office has rejected the relevant claims of the ‘483 patent that Magnolia Medical asserted against Kurin.

August 15, 2023
·
1 min read
Business

Wound Healing Technology Company Merakris Adds Two Executives to Leadership Team

Merakris Therapeutics has added two new executives to its leadership team as it prepares to expand its product line and increase its investigational new drug programs aimed at treating patients with chronic skin and tissue wounds that fail to heal properly.

August 15, 2023
·
5 min read
Business

Cardinal Health Reports Fourth Quarter and Full Year Results for Fiscal Year 2023 at High End of Investor Day Guidance

Cardinal Health reported fourth quarter fiscal year 2023 revenues of $53.5 billion, an increase of 13% from the fourth quarter of last year.

August 15, 2023
·
37 min read
Business

Visiopharm and Boston Cell Standards Announce Partnership to Develop Joint IHC Technology for Magnani-Taylor Regulatory Proposal

Visiopharm and Boston Cell Standards today announced a partnership to develop a joint technology solution that enables labs to meet key provisions of regulatory changes proposed in a groundbreaking editorial recently published in Archives of Pathology & Laboratory Medicine.

August 15, 2023
·
3 min read
Biotech Bay

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

Alterity Therapeutics Limited today announced that it has received a A$4.74 million cash refund from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive (R&DTI) Scheme.

August 15, 2023
·
2 min read
FDA

ImmPACT Bio Announces FDA Clearance of IND Application for Bispecific CD19/CD20 CAR T Therapy IMPT-514 for the Treatment of Refractory Systemic Lupus Erythematosus

ImmPACT Bio USA, Inc. today announced the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for IMPT-514, a bispecific CD19/CD20 CAR T therapy for the treatment of active, refractory systemic lupus erythematosus (SLE).

August 15, 2023
·
4 min read
Drug Development

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Galecto, Inc. today announced topline results from its Phase 2b GALACTIC-1 trial evaluating the safety and efficacy of inhaled GB0139 for the treatment of idiopathic pulmonary fibrosis (IPF).

August 15, 2023
·
6 min read
FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023

FSD Pharma Inc. is pleased to announce that its late breaking abstract about Phase 1 first-in-human data on Lucid-MS (Lucid-21-302) was selected for presentation at the upcoming MSMilan 2023 - 9th Joint ECTRIMS-ACTRIMS meeting scheduled for October 11-13, 2023.

August 15, 2023
·
7 min read
Lone Star Bio

Form Bio Announces Executive Webinar Featuring BCG, ElevateBio, and NVIDIA

Form Bio is hosting an executive webinar on exploring AI challenges and opportunities in biopharma, synthetic biology, and more.

August 15, 2023
·
1 min read